Quantum Biopharma Reports Positive Phase 1 Safety For Multiple Sclerosis Drug
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 05 2025
0mins
Source: Benzinga
Clinical Trial Success: Quantum Biopharma Ltd.'s subsidiary, Huge Biopharma Australia, has received a clinical study report confirming that its compound Lucid-MS is safe and tolerable in healthy adults, allowing for further development towards treating multiple sclerosis.
Stock Performance: Following the positive trial results, QNTM stock has seen significant growth over the past year, although it experienced an 8.63% decline recently, trading at $25.40.
Analyst Views on QNTM
About QNTM
Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. The Company has also licensed unbuzzd, a formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
